

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE LIST

(Use several sheets if necessary)

ATT. DOCKET NO.

11146/10904

APPLICANT

ESMON, Naomi L., et al.

FILING DATE

03/14/2002

SERIAL NO.

10/088,021

GROUP

unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5 4 7 2 8 5 2	12/05/95	Smirnov, et al.	C12Q	1/56	09/15/93
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
					YES NO
AL					
AM					
AN					
AO					
AP					

(Including Author, Title, Date, Pertinent Pages, Etc.).

AR	Aviram, et al., 1991. "Oxidized low-density lipoprotein reduces plasma coagulation in-vitro," Scand J Lab Invest 51:17-21
AS	Barrowcliffe, et al. 1981. "Studies of phospholipid reagents used in coagulation I: general properties and their sensitivity to Factor VIII," Thromb Haemostas 46:629-633
AT	Barrowcliffe, et al. 1981. "Phospholipid reagents used in coagulation II: factors influencing their sensitivity to heparin," Thromb Haemostas 46:634-637

MINER

DATE CONSIDERED

6/16/04

MINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if
not in conformance and not considered. Include copy of this form with next communication to application.

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE LIST

(Use several sheets if necessary)

ATT. DOCKET NO.

11146/10904

APPLICANT

ESMON, Naomi, L., et al.

FILING DATE

03/14/2002

SERIAL NO.

10/088,021

GROUP

unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	BL							
	BM							
	BN							
	BO							
	BP							

(Including Author, Title, Date, Pertinent Pages, Etc.).

6	BR		Billy, et al. 1995. "Prothrombin contributes to the assembly of the factor Va-factor Xa complex at phosphatidylserine-containing phospholipid membranes," <i>J Biol Chem</i> 270:26883-26889
6	BS		Esmon, C.T. and Schwarz, H.P. 1995. "An update on clinical and basic aspects of the protein C anticoagulant pathway," <i>Trends Cardiovasc Med</i> 5:141-148
6	BT		Esmon, et al. 2000. "Antiphospholipid antibodies and the protein C pathway," <i>Autoimmunity</i> 15:221-225
EXAMINER <u>[Signature]</u> DATE CONSIDERED <u>6/16/04</u>			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.			

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE LIST (Use several sheets if necessary)	ATT. DOCKET NO.	SERIAL NO.
	11146/10904	10/088,021
	APPLICANT	
	ESMON, Naomi, L., et al.	
	FILING DATE	GROUP
	03/14/2002	unassigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	CA						
	CB						
	CC						
	CD						
	CE						
	CF						
	CG						
	CH						
	CI						
	CJ						
	CK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	CL							
	CM							
	CN							
	CO							
	CP							

(Including Author, Title, Date, Pertinent Pages, Etc.).

8	CR	Furie, B. and Furie, B.C. 1988. "The molecular basis of blood coagulation," Cell 53:505-518
5	CS	Gilbert, G.E. and Arena, A.A. 1995. "Phosphatidylethanolamine induces high affinity binding sites for factor VIII on membranes containing phosphatidyl-L-serine," J Biol Chem 270:18500-18505
4	CT	Horkko, et al. 1996. "Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids," J Clin Invest 98:845-853
EXAMINER	DATE CONSIDERED 6/16/04	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.		

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE LIST (Use several sheets if necessary)	ATT. DOCKET NO.	SERIAL NO.
	11146/10904	10/088,021
	APPLICANT	
	ESMON, Naomi, L., et al.	
	FILING DATE	GROUP
	03/14/2002	unassigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	DA						
	DB						
	DC						
	DD						
	DE						
	DF						
	DG						
	DH						
	DI						
	DJ						
	DK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	DL							
	DM							
	DN							
	DO							
	DP							

(Including Author, Title, Date, Pertinent Pages, Etc.).

65	DR	Jain, S.K. 1985. "In vivo externalization of phosphatidylserine and phosphatidylethanolamine in the membrane bilayer and hypercoagulability by the lipid peroxidation of erythrocytes in rats," <i>J Clin Invest</i> 76:281-286
8	DS	Lesnik, et al. 1995. "Tissue factor pathway inhibitor activity associated with LDL is inactivated by cell- and copper-mediated oxidation," <i>Arteriosclerosis, Thrombosis and Vascular Biology</i> 15:1121-1130
8	DT	Malech, H.L. and Gallin, J.I. 1987. "Neutrophils in human diseases," <i>N Engl J Med</i> 317:687-694

EXAMINER

DATE CONSIDERED

6/16/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE LIST (Use several sheets if necessary)	ATT. DOCKET NO.	SERIAL NO.
	11146/10904	10/088,021
	APPLICANT	
	ESMON, Namoi, L., et al.	GROUP
	FILING DATE	unassigned
	03/14/2002	

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	EA						
	EB						
	EC						
	ED						
	EE						
	EF						
	EG						
	EH						
	EI						
	EJ						
	EK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	EL						
	EM						
	EN						
	EO						
	EP						

(Including Author, Title, Date, Pertinent Pages, Etc.).

ER		Mann, et al. 1988. "Cofactor proteins in the assembly and expression of blood clotting enzyme complexes,"
	✓	Ann Rev Biochem 57:915-956
ES	✓	McCord, J.M. 1985. "Oxygen-derived free radicals in postischemic tissue injury,"
	✓	N Engl J Med 312:159-163
ET		Neuenschwander, et al. 1995. "Phosphatidylethanolamine augments factor VIIa-tissue factor activity: enhance
	✓	ment of sensitivity to phosphatidylserine," Biochemistry 34:13988-13993

EXAMINER: *[Signature]* DATE CONSIDERED: *6/16/04*

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE LIST (Use several sheets if necessary)		ATT. DOCKET NO.		SERIAL NO.	
		11146/10904		10/088,021	
		APPLICANT			
		ESMON, Naomi, L., et al.			
		FILING DATE		GROUP	
		03/14/2002		unassigned	

U.S. PATENT DOCUMENTS												
*EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	FA											
	FB											
	FC											
	FD											
	FE											
	FF											
	FG											
	FH											
	FI											
	FJ											
	FK											

FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
													YES	NO
	FL													
	FM													
	FN													
	FO													
	FP													

(Including Author, Title, Date, Pertinent Pages, Etc.).

5	FR		Pei, et al. 1993. "Specific contribution of different phospholipid surfaces to the activation of prothrombin by the
		✓	fully assembled prothrombinase," <i>J Biol Chem</i> 268:3226-3233
4	FS		Rauch, et al. 1986. "Human hybridoma lupus anticoagulants distinguish between lamellar and hexagonal phase
		✓	lipid systems," <i>J Biol Chem</i> 261: 9672-9677
4	FT		Smeets, et al. 1996. "Contribution of different phospholipid classes to the prothrombin converting capacity of
		✓	sonicated lipid vesicles," <i>Thromb Res</i> 81:419-426

EXAMINER <i>[Signature]</i>	DATE CONSIDERED <i>6/16/04</i>	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.		

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE LIST (Use several sheets if necessary)		ATT. DOCKET NO.		SERIAL NO.	
		11146/10904		10/088,021	
		APPLICANT			
		ESMON, Naomi, L., et al.			
		FILING DATE		GROUP	
		03/14/2002		unassigned	

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	GA						
	GB						
	GC						
	GD						
	GE						
	GF						
	GG						
	GH						
	GI						
	GJ						
	GK						

FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	GL						
	GM						
	GN						
	GO						
	GP						

(Including Author, Title, Date, Pertinent Pages, Etc.).		
GR		Smirnov, M.D. and Esmon, C.T. 1994. "Phosphatidylethanolamine incorporation into vesicles selectively enhances factor Va inactivation by activated protein," <i>J Biol Chem</i> 269:816-819
GS		Smirnov, et al. 1995. "On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies," <i>J Clin Invest</i> 94:309-316
GT		Smirnov, et al. 1999. "The effect of membrane composition on the hemostatic balance," <i>Biochem</i> 38:3591-3598

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.	6/16/04